Bioxodes receives a repayable advance of EUR 500.000 from the Walloon Region
In 2017, Bioxodes received a repayable advance of EUR 550.000 in non-dilutive funding (repayable advance) from the Walloon Region.
Bioxodes raises EUR 7.9 million to bring Ir-CPI to the clinic
Marche-en-Famenne, Belgium, 2015 – Bioxodes SA, the Belgian-based start-up announces that it received EUR 7.9 million to bring Ir-CPI to the clinic. In 2015, Bioxodes closed a EUR 5.2 million Series A financing roud with existing shareholders, new business angels and new Belgian investment fund (SFPI, Sambrinvest) and received a repayable advance of EUR 2.7 million in non-dilutive funding from the Walloon Region (DG06).
Bioxodes’ antithrombotic meets development milestones – Company to launch Series A financing round to bring product to the clinic
Marche-en-Famenne, Belgium, 2015 – Bioxodes SA, the Belgian-based start-up developing pharmaceutical products derived from natural sources, announces that it has successfully brought its lead product, Ir-CPI, trough pre-clinical development confirming its potential as the first in a new class of antithrombotic medicines. The company is now poised to initiate the studies required for clinical entry.
Bioxodes raises EUR 2.6 million to develop antithrombotic peptide derived from tick saliva
Marche-en-Famenne, Belgium, November 2013 - Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million first seed funding round with a consortium of business angels and Belgian investment funds. EUR 1.6 million is from the European Regional Development Fund (ERDF) and the Walloon Region in Belgium via the Retech program for Research & Technology.